Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 1998

View Archived Issues

Onyx expands ONYX-015 clinical trials in pancreatic cancer

Janssen terminates Avicidin agreement with NeoRx

Intercardia and Astra end Bextra collaboration

Astra initiates atherosclerosis research collaboration with Oxagen

Review of the preclinical activity of GAR-936, a glycylcycline antibiotic with clinical potential

Potent analgesic agents from HMR with additional pharmacological effects

ADIR claims 2-aminoindanes for CNS disorders involving serotonergic system dysfunction

Voriconazole, a promising treatment for serious fungal infections

MMP inhibitors from Bayer particularly useful for osteoarthritis and tumor metastasis

Ono describes new prostanoid receptor ligands

Cell adhesion inhibitors developed by Sumitomo researchers

Abbott uses TE-802 as lead to develop broader spectrum ketolides

Glaxo Wellcome's MMP inhibitor shows potential in treating sepsis in early clinical study

Cubist and Novalon identify small-molecule inhibitors of bacterial enzyme

Xoma presents recombinant variant of rBPI21 with potent antiinfective activity

Inhibitors of bacterial protein identified at Cubist

New echinocandin antifungal discovered by Fujisawa profiled up to phase I at ICAAC

L-084 selected for further development as oral carbapenem prodrug

Pfizer presents a new macrolide that retains good activity in macrolide-resistant strains

Sarawak MediChem initiates phase Ib trial of (+)-calanolide A

Novavax presents BCTP, a novel antimicrobial nanoemulsion, at ICAAC

Icos and Lilly join forces to develop PDE5 inhibitors for sexual dysfunction

Thalomid now available for prescribing in U.S.

First launch for Dainippon's prokinetic agent

First MMP inhibitor cleared for marketing as adjunct in periodontitis

IRL-3630, a bifunctional ETA/ETB receptor antagonist in preliminary testing at Novartis

NO-NSAIDs licensed by NicOx to Astra for pain and inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...